DY
STAB

Dowling & Yahnke’s Statera Biopharma, Inc. Common Stock STAB Stock Holding History

Dowling & Yahnke’s Portfolio STAB Stock Details STAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$4K Hold
28,875
– – ﹤0.01% 373
2022
Q2 		$8K Hold
28,875
– – ﹤0.01% 374
2022
Q1 		$9K Buy
28,875
+14,200
+97% +$15.2K ﹤0.01% 374
2021
Q4 		$34K Hold
14,675
– – ﹤0.01% 376
2021
Q3 		$34K Buy
+14,675
New +$55.6K ﹤0.01% 371

Other funds holding STAB

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RJFSA
Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return

Dowling & Yahnke's STAB Position: Q3 2022 in Review

Dowling & Yahnke held its Statera Biopharma, Inc. Common Stock (STAB) position steady in Q3 2022 at 28,875 shares worth $4K. The position accounts for ﹤0.01% of the portfolio, ranked #373.

Dowling & Yahnke first reported a position in STAB in Q3 2021 and has held it in 5 quarters since. The position peaked at $34K in Q4 2021. 35 funds tracked by Wall St. Rank hold STAB as of Q3 2022.

  • Dowling & Yahnke held 28,875 shares of Statera Biopharma, Inc. Common Stock worth $4K as of Q3 2022.
  • Dowling & Yahnke left its Statera Biopharma, Inc. Common Stock share count unchanged in Q3 2022.
  • Statera Biopharma, Inc. Common Stock made up ﹤0.01% of Dowling & Yahnke's portfolio in Q3 2022, its #373 holding.
  • Dowling & Yahnke first reported a position in Statera Biopharma, Inc. Common Stock in Q3 2021 and has held it in 5 quarters since.
  • Dowling & Yahnke's Statera Biopharma, Inc. Common Stock position peaked at $34K in Q4 2021.
  • 35 funds tracked by Wall St. Rank held Statera Biopharma, Inc. Common Stock as of Q3 2022.

Based on Dowling & Yahnke's 13F filing for Q3 2022, filed 3 Nov 2022.